ClinicalTrials.gg
CompletedNCT01335477Updated Jul 25, 2016Results posted

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II

A Phase 3 interventional study of placebo and BIBF 1120 in Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 108 sites in 17 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-07-25.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
551
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 128 studies in Pulmonary Fibrosis with a site in United States — 30 open to participants now, 42 under way, 5 of them phase 3. Pulmonary Fibrosis · United States.

Enrollment
6th of 90
551 · median 50
Started
2011
with 7 others
Phase 3
15 of 128
2 open now
Registered
47th of 128
by date
Lead sponsor
3 of 128
Boehringer Ingelheim

Among the 128 studies in Pulmonary Fibrosis with a site in United States, this one is the 6th largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2011, is one of 15 in phase 3, and was the 47th registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

30 of the 128 studies in Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

Idiopathic Pulmonary Fibrosis (IPF) is a chronic disease of unknown cause that results in scarring of the lung and there is a high unmet medical need for effective treatment to halt lung function decline, delay or avoid exacerbation (flare-ups), and ultimately to reduce the death rate.

In a large Phase 2 trial (1199.30) (NCT00514683), investigating the effects of 52 weeks of treatment with BIBF 1120 in patients with IPF, a positive effect was seen on lung function of patients treated with high dose of BIBF 1120 compared to placebo.

Hence it is the purpose of this trial to investigate and confirm the efficacy and safety of BIBF 1120 at a high dose in treating patients with IPF, compared with placebo. The trial will be conducted as a prospective, randomised design with the aim to collect safety and efficacy data.

Respiratory function is globally accepted for assessment of treatment effects in IPF patients. The chosen endpoint (Forced Vital Capacity (FVC) decline) is easy to obtain and is part of the usual examinations done in IPF patients.

03

Conditions studied

  • Pulmonary Fibrosis

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >= 40 years;
  2. IPF diagnosed, according to most recent American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), Latin American Thoracic Association (ALAT) IPF guideline for diagnosis and management, within 5 years;
  3. Combination of High Resolution Computerized Tomography (HRCT) pattern, and if available surgical lung pattern, as assessed by central reviewers, are consistent with diagnosis of IPF
  4. Dlco (corrected for ): 30%-79% predicted of normal; 5.FVC>= 50% predicted of normal

Exclusion criteria

Exclusion criteria:

  1. (AST), Alanine Aminotransferase (ALT) > 1.5 x (ULN)
  2. > 1.5 x ULN;
  3. Relevant airways obstruction (i.e. pre-bronchodilator /FVC \< 0.7);
  4. Patient likely to have lung transplantation during study (being on transplantation list is acceptable for participation);
  5. Myocardial infarction within 6 months;
  6. Unstable angina within 1 month;
  7. Bleeding risk (genetic predisposition; fibrinolysis or full-dose therapeutic anticoagulation or high dose antiplatelet therapy; history of hemorrhagic CNS event within 12 months; haemoptysis or haematuria or active gastro-intestinal bleeding or ulcers or major injury or surgery within 3 months);
  8. Thrombotic risk (inherited predisposition; history of thrombotic event (including stroke and ) within 12 months;
  9. (INR) > 2, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT) by > 50% of institutional ULN);
  10. N-ACetyl Cystein, prednisone > 15mg/day or equivalent received within 2 weeks of visit 1;
  11. Pirfenidone, azathioprine, cyclophosphamide, cyclosporine A received within 8 weeks of visit 1;
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
551 participants (actual)

Study arms

  • Placebo comparator
    placebo

    patient receives capsules identical to those containing active drug

    Drug: placebo

  • Experimental
    BIBF 1120

    patient receives capsules containing BIBF 1120 twice a day

    Drug: BIBF 1120

Interventions

  • Drugplacebo

    placebo matching BIBF 1120 BID

  • BIBF 1120 BID (twice daily)

06

What researchers measure

Primary outcomes

  1. Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks.

    Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. For this endpoint reported means represent the adjusted rate.

    Time frame: 52 weeks

Secondary outcomes

  1. Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks

    This is a key secondary endpoint. SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact. The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status. Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

    Time frame: Baseline and 52 weeks

  2. Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation

    Due to rare events, the median of time to event is not calculable, thus the percentages of patients with (IPF) exacerbation are reported and represented as a key secondary endpoint. An acute exacerbation (reported as an AE by the investigator) was defined as follows: Otherwise unexplained clinical features including all of the following: Unexplained worsening or development of dyspnoea within 30 days New diffuse pulmonary infiltrates on chest X-ray, and/or new HRCT parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit Exclusion of infection as per routine clinical practice and microbiological studies Exclusion of alternative causes as per routine clinical practice including left heart failure, pulmonary embolism and identifiable cause of acute lung injury. Failure is the proportion of patients with at least one acute IPF exacerbation over 52 weeks, based on all investigator-reported AEs .

    Time frame: 52 weeks

  3. Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks

    Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).

    Time frame: Baseline and 52 weeks

  4. Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks

    Percentage change from baseline in FVC over 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).

    Time frame: Baseline and 52 weeks

  5. Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks

    Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).

    Time frame: Baseline and 52 weeks

  6. Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks

    Percentage change from baseline in FVC (% predicted) at 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).

    Time frame: Baseline and 52 weeks

  7. Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold

    Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 5% threshold (decrease by \>5%, increase by \>5%, and change within ≤5%).

    Time frame: Baseline and 52 weeks

  8. Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold

    Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 10% threshold (decrease by 10%, increase by \>10%, and change within ≤10%)

    Time frame: Baseline and 52 weeks

  9. FVC Responders Using 10% Threshold at 52 Weeks

    FVC responders using 10% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 10% and with an FVC evaluation at 52 weeks.

    Time frame: 52 weeks

  10. Proportion of FVC Responders Using 5% Threshold at 52 Weeks

    Proportion of FVC responders using 5% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 5% and with an FVC evaluation at 52 weeks.

    Time frame: 52 weeks

  11. Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)

    Proportion of SGRQ responders at 52 weeks. Responders defined as \<= -4 points change in change from baseline in SGRQ total score at 52 weeks.

    Time frame: baseline and 52 weeks

  12. Change From Baseline in SGRQ Symptom Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

    SGRQ Symptom score is a sub-component of SGRQ total score and is concerned with the effect of respiratory symptoms, their frequency and severity. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better symptom-related quality of life. Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

    Time frame: baseline and 52 weeks

  13. Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

    SGRQ Impact score is a sub-component of SGRQ total score and covers a range of aspects concerned with social functioning and psychological disturbances resulting from airway disease. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better impact-related quality of life. Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

    Time frame: baseline and 52 weeks

  14. Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

    SGRQ Activity score is a sub-component of SGRQ total score and concerned with activities that cause or are limited by breathlessness. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better activity-related quality of life. Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

    Time frame: baseline and 52 weeks

  15. Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

    SGRQ-I is the IPF specific version of SGRQ comprises of selected items from the SGRQ divided into three components, Symptoms, Activity and Impact. Each component is scored separately. The weights for all items with a positive responses are summed and the weights from missed items are deducted from the maximum possible weight for the total score. The total score is calculated by dividing the summed weights from positive items in the questionnaire by maximum possible weight for all items in the questionnaire. The total score can range from 0 to 100 with a lower score denoting a better health-related quality of life. Change from baseline is calculated as the difference between total score at week 52 and total score at baseline as measured by the scale.

    Time frame: baseline and 52 weeks

  16. Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)

    Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

    Time frame: baseline and 52 weeks

  17. Change From Baseline in Cough Symptom Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)

    The cough domains of the Cough and Sputum Assessment Questionnaire (CASAQ(CD)) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

    Time frame: baseline and 52 weeks

  18. Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)

    The cough domains of the Cough and Sputum Assessment Questionnaire (CASA- Q) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

    Time frame: baseline and 52 weeks

  19. Proportion of Patient's Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)

    Patient's Global Impression of Change (PGI-C) responders are defined as 'Very much better'/ 'Much better'/ 'A little better'/ 'No change'.

    Time frame: 52 weeks

  20. Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks : Patient Reported Outcomes (PROs)

    The EuroQol 5-dimensional Health State is based on a visual analog scale (EQ-VAS) representing the general patient's health state labelled from 100 (best imaginable health state) to 0 (worst imaginable health state). A higher score indicating a better health state. Change from baseline is calculated as the difference between health state at week 12, 24 and 52 respectively and health state at baseline as measured by the scale.

    Time frame: baseline, 12 weeks, 24 weeks and 52 weeks

  21. Risk of an Acute IPF Exacerbation Over 52 Weeks

    The incidence rate of exacerbations (calculated as the number of patients with at least 1 acute IPF exacerbation divided by the total number of years at risk in years\*100)

    Time frame: 52 weeks

  22. Time to Death Over 52 Weeks

    Due to rare events, the median of time to event is not calculable, thus the percentages of patients who did or did not experienced death before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the proportion of patients who died over 52 weeks (373 days time-period).

    Time frame: 52 weeks

  23. Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)

    Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death due to respiratory causes before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the the proportion of patients who died due to respiratory causes over 52 weeks (373 days time-period).

    Time frame: 52 weeks

  24. Time to On-treatment Death

    Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not die before or at last trial medication intake + 28 days were censored at last trial medication intake + 28 days and reported. Failure is the the proportion of patients who died on-treatment.

    Time frame: 52 weeks

  25. Time to Death or Lung Transplant Over 52 Weeks

    Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experience event (death or lung transplant) before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the proportion of patients who died or had lung transplant over 52 weeks (373 days time-period).

    Time frame: 52 weeks

  26. Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.

    Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death or lung transplant or qualifying for lung transplant over 52 weeks are reported. A patient was considered qualifying for lung transplant by the investigator if he or she fulfilled the following criteria: FVC \<45% predicted or Carbon monoxide diffusion capacity (DL(CO)) \<30% pred or Oxygen saturation on pulse oximetry (SpO2) \<88% at rest, at sea level (to be adapted for other heights). These criteria were evaluated by investigators judgement. Failure is the proportion of patients who died or had lung transplant or qualified for lung transplant over 52 weeks (373 days time-period).

    Time frame: 52 weeks

  27. Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks

    Means presented are the adjusted means. Adjusted mean is based on all analyzed patients in the model (not only patients with a change from baseline to week 52)

    Time frame: baseline and 52 weeks

  28. Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks

    Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).

    Time frame: baseline and 52 weeks

07

Results

Posted Feb 13, 2015

Participant flow

Participant flow — Overall Study
MilestonePlaceboNintedanib 150 mg Bid
Started220331
Completed179272
Not completed4159
Withdrew: Adverse event3042
Withdrew: Non compliant with protocol02
Withdrew: Lost to follow-up12
Withdrew: Consent withdrawn, not due to ae79
Withdrew: Not treated12
Withdrew: Reason other than those stated above22

Outcome measures

PrimaryAnnual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks.

Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. For this endpoint reported means represent the adjusted rate.

Time frame:
52 weeks
Reported as:
Mean · mL/year
Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks.
mL/yearPlaceboNintedanib 150 mg Bid
Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks.-207.32 ± 19.309-113.59 ± 15.726
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Random coefficient regression · p = 0.0002 (The objective of this trial was to assess the superiority of nintedanib 150 mg bid compared to placebo on the annual rate of decline in FVC.) · Mean difference (final values): 93.73 · 95% CI 44.78 to 142.68Within-patient errors are modelled by an Unstructured variance-covariance matrix. Inter-individual variability is modelled by a Variance-components variance-covariance matrix. Nintedanib 150 mg bid versus Placebo.
SecondaryChange From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks

This is a key secondary endpoint. SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact. The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status. Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

Time frame:
Baseline and 52 weeks
Reported as:
Mean · points on a scale
Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks
points on a scalePlaceboNintedanib 150 mg Bid
Change From Baseline in Saint George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks5.48 ± 0.8912.80 ± 0.730
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Mixed Models Analysis · p = 0.0197 · Mean difference (final values): -2.69 · 95% CI -4.95 to -0.43Within-patient errors are modelled by compound symmetry covariance matrix. Nintedanib 150 mg bid versus Placebo.
SecondaryTime to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation

Due to rare events, the median of time to event is not calculable, thus the percentages of patients with (IPF) exacerbation are reported and represented as a key secondary endpoint. An acute exacerbation (reported as an AE by the investigator) was defined as follows: Otherwise unexplained clinical features including all of the following: Unexplained worsening or development of dyspnoea within 30 days New diffuse pulmonary infiltrates on chest X-ray, and/or new HRCT parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit Exclusion of infection as per routine clinical practice and microbiological studies Exclusion of alternative causes as per routine clinical practice including left heart failure, pulmonary embolism and identifiable cause of acute lung injury. Failure is the proportion of patients with at least one acute IPF exacerbation over 52 weeks, based on all investigator-reported AEs .

Time frame:
52 weeks
Reported as:
Number · percentage of participants
Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation
percentage of participantsPlaceboNintedanib 150 mg Bid
Failure9.63.6
Censored90.496.4
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Log Rank · p = 0.0050 · Hazard ratio (hr): 0.38 · 95% CI 0.19 to 0.77Nintedanib 150 mg bid versus Placebo.
SecondaryAbsolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks

Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).

Time frame:
Baseline and 52 weeks
Reported as:
Mean · mL
Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks
mLPlaceboNintedanib 150 mg Bid
Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks-205.03 ± 16.629-95.26 ± 14.200
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 109.77 · 95% CI 70.92 to 148.62Within-patient errors are modelled by compound symmetry covariance matrix. Nintedanib 150 mg bid versus Placebo.
SecondaryRelative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks

Percentage change from baseline in FVC over 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).

Time frame:
Baseline and 52 weeks
Reported as:
Mean · percent change
Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks
percent changePlaceboNintedanib 150 mg Bid
Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks-8.14 ± 0.620-3.90 ± 0.528
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 4.24 · 95% CI 2.78 to 5.69Within-patient errors are modelled by compound symmetry covariance matrix. Nintedanib 150 mg bid versus Placebo.
SecondaryAbsolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks

Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).

Time frame:
Baseline and 52 weeks
Reported as:
Mean · %predicted
Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks
%predictedPlaceboNintedanib 150 mg Bid
Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks-6.15 ± 0.505-3.09 ± 0.433
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 3.06 · 95% CI 1.87 to 4.25Within-patient errors are modelled by compound symmetry covariance matrix. Nintedanib 150 mg bid versus Placebo.
SecondaryRelative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks

Percentage change from baseline in FVC (% predicted) at 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).

Time frame:
Baseline and 52 weeks
Reported as:
Mean · percent change
Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks
percent changePlaceboNintedanib 150 mg Bid
Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks-8.13 ± 0.614-3.92 ± 0.525
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 4.21 · 95% CI 2.76 to 5.67Within-patient errors are modelled by compound symmetry covariance matrix. Nintedanib 150 mg bid versus Placebo.
SecondaryAbsolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold

Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 5% threshold (decrease by \>5%, increase by \>5%, and change within ≤5%).

Time frame:
Baseline and 52 weeks
Reported as:
Number · percentage of participants
Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold
percentage of participantsPlaceboNintedanib 150 mg Bid
Decrease > 5%52.234.9
Change within ≤ 5%45.050.2
Increase > 5%2.814.9
SecondaryAbsolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold

Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 10% threshold (decrease by 10%, increase by \>10%, and change within ≤10%)

Time frame:
Baseline and 52 weeks
Reported as:
Number · percentage of participants
Absolute Categorical Change From Baseline of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold
percentage of participantsPlaceboNintedanib 150 mg Bid
Decrease > 10%22.214.9
Change within ≤ 10%77.280.7
Increase > 10%0.64.5
SecondaryFVC Responders Using 10% Threshold at 52 Weeks

FVC responders using 10% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 10% and with an FVC evaluation at 52 weeks.

Time frame:
52 weeks
Reported as:
Number · percentage of participants
FVC Responders Using 10% Threshold at 52 Weeks
percentage of participantsPlaceboNintedanib 150 mg Bid
FVC Responders Using 10% Threshold at 52 Weeks63.93 (57.38 to 70.00)69.60 (64.43 to 74.33)
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Regression, Logistic · p = 0.1833 · Odds ratio (or): 1.286 · 95% CI 0.89 to 1.86Nintedanib 150 mg bid versus Placebo
SecondaryProportion of FVC Responders Using 5% Threshold at 52 Weeks

Proportion of FVC responders using 5% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 5% and with an FVC evaluation at 52 weeks.

Time frame:
52 weeks
Reported as:
Number · percentage of participants
Proportion of FVC Responders Using 5% Threshold at 52 Weeks
percentage of participantsPlaceboNintedanib 150 mg Bid
Proportion of FVC Responders Using 5% Threshold at 52 Weeks39.27 (33.04 to 45.87)53.19 (47.79 to 58.52)
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Regression, Logistic · p = 0.0011 · Odds ratio (or): 1.794 · 95% CI 1.26 to 2.55Nintedanib 150 mg bid versus Placebo
SecondaryProportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)

Proportion of SGRQ responders at 52 weeks. Responders defined as \<= -4 points change in change from baseline in SGRQ total score at 52 weeks.

Time frame:
baseline and 52 weeks
Reported as:
Number · percentage of participants
Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)
percentage of participantsPlaceboNintedanib 150 mg Bid
Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)16.89 (12.51 to 22.42)25.23 (20.84 to 30.19)
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Regression, Logistic · p = 0.0218 · Odds ratio (or): 1.664 · 95% CI 1.08 to 2.57Nintedanib 150 mg bid versus Placebo
SecondaryChange From Baseline in SGRQ Symptom Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

SGRQ Symptom score is a sub-component of SGRQ total score and is concerned with the effect of respiratory symptoms, their frequency and severity. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better symptom-related quality of life. Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

Time frame:
baseline and 52 weeks
Reported as:
Mean · points on a scale
Change From Baseline in SGRQ Symptom Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
points on a scalePlaceboNintedanib 150 mg Bid
Change From Baseline in SGRQ Symptom Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)3.43 ± 1.2972.03 ± 1.061
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Mixed Models Analysis · p = 0.4019 · Mean difference (final values): -1.40 · 95% CI -4.69 to 1.88Within-patient errors are modelled by compound symmetry covariance matrix. Nintedanib 150 mg bid versus Placebo.
SecondaryChange From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

SGRQ Impact score is a sub-component of SGRQ total score and covers a range of aspects concerned with social functioning and psychological disturbances resulting from airway disease. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better impact-related quality of life. Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

Time frame:
baseline and 52 weeks
Reported as:
Mean · points on a scale
Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
points on a scalePlaceboNintedanib 150 mg Bid
Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)5.93 ± 1.0362.85 ± 0.852
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Mixed Models Analysis · p = 0.0220 · Mean difference (final values): -3.08 · 95% CI -5.71 to -0.45Within-patient error are modelled by compound symmetry covariance matrix. Nintedanib 150 mg bid versus Placebo.
SecondaryChange From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

SGRQ Activity score is a sub-component of SGRQ total score and concerned with activities that cause or are limited by breathlessness. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better activity-related quality of life. Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

Time frame:
baseline and 52 weeks
Reported as:
Mean · points on a scale
Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
points on a scalePlaceboNintedanib 150 mg Bid
Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)7.20 ± 1.0523.89 ± 0.863
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Mixed Models Analysis · p = 0.0152 · Mean difference (final values): -3.31 · 95% CI -5.97 to -0.64Within-patient errors are modelled by compound symmetry covariance matrix. Nintedanib 150 mg bid versus Placebo.
SecondaryChange From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)

SGRQ-I is the IPF specific version of SGRQ comprises of selected items from the SGRQ divided into three components, Symptoms, Activity and Impact. Each component is scored separately. The weights for all items with a positive responses are summed and the weights from missed items are deducted from the maximum possible weight for the total score. The total score is calculated by dividing the summed weights from positive items in the questionnaire by maximum possible weight for all items in the questionnaire. The total score can range from 0 to 100 with a lower score denoting a better health-related quality of life. Change from baseline is calculated as the difference between total score at week 52 and total score at baseline as measured by the scale.

Time frame:
baseline and 52 weeks
Reported as:
Mean · points on a scale
Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
points on a scalePlaceboNintedanib 150 mg Bid
Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)5.84 ± 0.9212.72 ± 0.757
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Mixed Models Analysis · p = 0.0089 · Mean difference (final values): -3.12 · 95% CI -5.46 to -0.79Within-patient errors are modelled by compound symmetry covariance matrix. Nintedanib 150 mg bid versus Placebo.
SecondaryChange From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)

Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

Time frame:
baseline and 52 weeks
Reported as:
Mean · points on a scale
Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)
points on a scalePlaceboNintedanib 150 mg Bid
Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)9.07 ± 1.3006.69 ± 1.073
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Mixed Models Analysis · p = 0.1587 · Mean difference (final values): -2.38 · 95% CI -5.68 to 0.93Within-patient errors are modelled by compound symmetry covariance matrix. Nintedanib 150 mg bid versus Placebo.
SecondaryChange From Baseline in Cough Symptom Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)

The cough domains of the Cough and Sputum Assessment Questionnaire (CASAQ(CD)) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

Time frame:
baseline and 52 weeks
Reported as:
Mean · points on a scale
Change From Baseline in Cough Symptom Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)
points on a scalePlaceboNintedanib 150 mg Bid
Change From Baseline in Cough Symptom Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)-2.38 ± 1.325-0.33 ± 1.087
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Mixed Models Analysis · p = 0.2326 · Mean difference (final values): 2.05 · 95% CI -1.31 to 5.41Within-patient errors are modelled by compound symmetry covariance matrix. Nintedanib 150 mg bid versus Placebo.
SecondaryChange From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)

The cough domains of the Cough and Sputum Assessment Questionnaire (CASA- Q) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).

Time frame:
baseline and 52 weeks
Reported as:
Mean · points on a scale
Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)
points on a scalePlaceboNintedanib 150 mg Bid
Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)-4.39 ± 1.209-2.58 ± 0.991
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Mixed Models Analysis · p = 0.2475 · Mean difference (final values): 1.81 · 95% CI -1.26 to 4.88Within-patient errors are modelled by compound symmetry covariance matrix. Nintedanib 150 mg bid versus Placebo
SecondaryProportion of Patient's Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)

Patient's Global Impression of Change (PGI-C) responders are defined as 'Very much better'/ 'Much better'/ 'A little better'/ 'No change'.

Time frame:
52 weeks
Reported as:
Number · percentage of participants
Proportion of Patient's Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)
percentage of participantsPlaceboNintedanib 150 mg Bid
Proportion of Patient's Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)53.88 (47.27 to 60.36)61.70 (56.34 to 66.79)
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Regression, Logistic · p = 0.0690 · Odds ratio (or): 1.379 · 95% CI 0.98 to 1.95Nintedanib 150 mg bid versus Placebo
SecondaryChange From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks : Patient Reported Outcomes (PROs)

The EuroQol 5-dimensional Health State is based on a visual analog scale (EQ-VAS) representing the general patient's health state labelled from 100 (best imaginable health state) to 0 (worst imaginable health state). A higher score indicating a better health state. Change from baseline is calculated as the difference between health state at week 12, 24 and 52 respectively and health state at baseline as measured by the scale.

Time frame:
baseline, 12 weeks, 24 weeks and 52 weeks
Reported as:
Mean · points on a scale
Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks : Patient Reported Outcomes (PROs)
points on a scalePlaceboNintedanib 150 mg Bid
12 weeks (N=207, 306)-1.48 ± 15.60-0.57 ± 16.97
24 weeks (N=204, 297)-4.86 ± 16.94-1.10 ± 16.81
52 weeks (N=178, 265)-5.60 ± 17.67-2.52 ± 16.95
SecondaryRisk of an Acute IPF Exacerbation Over 52 Weeks

The incidence rate of exacerbations (calculated as the number of patients with at least 1 acute IPF exacerbation divided by the total number of years at risk in years\*100)

Time frame:
52 weeks
Reported as:
Number · Participants/Year *100
Risk of an Acute IPF Exacerbation Over 52 Weeks
Participants/Year *100PlaceboNintedanib 150 mg Bid
Risk of an Acute IPF Exacerbation Over 52 Weeks10.23.9
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Normal distribution · p = 0.0070 · Risk ratio (rr): 0.38 · 95% CI 0.19 to 0.77Nintedanib 150 mg bid versus Placebo
SecondaryTime to Death Over 52 Weeks

Due to rare events, the median of time to event is not calculable, thus the percentages of patients who did or did not experienced death before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the proportion of patients who died over 52 weeks (373 days time-period).

Time frame:
52 weeks
Reported as:
Number · percentage of participants
Time to Death Over 52 Weeks
percentage of participantsPlaceboNintedanib 150 mg Bid
Failure9.16.7
Censored90.993.3
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Log Rank · p = 0.2995 · Hazard ratio (hr): 0.74 · 95% CI 0.40 to 1.35Nintedanib 150 mg bid versus Placebo
SecondaryTime to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)

Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death due to respiratory causes before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the the proportion of patients who died due to respiratory causes over 52 weeks (373 days time-period).

Time frame:
52 weeks
Reported as:
Number · percentage of participants
Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)
percentage of participantsPlaceboNintedanib 150 mg Bid
Failure5.04.3
Censored95.095.7
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Log Rank · p = 0.6654 · Hazard ratio (hr): 0.86 · 95% CI 0.39 to 1.90Nintedanib 150 mg bid versus Placebo
SecondaryTime to On-treatment Death

Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not die before or at last trial medication intake + 28 days were censored at last trial medication intake + 28 days and reported. Failure is the the proportion of patients who died on-treatment.

Time frame:
52 weeks
Reported as:
Number · percentage of participants
Time to On-treatment Death
percentage of participantsPlaceboNintedanib 150 mg Bid
Failure7.84.9
Censored92.295.1
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Log Rank · p = 0.2209 · Hazard ratio (hr): 0.68 · 95% CI 0.34 to 1.35Nintedanib 150 mg bid versus Placebo
SecondaryTime to Death or Lung Transplant Over 52 Weeks

Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experience event (death or lung transplant) before or at 372 days after randomisation or last contact date (whichever occurs first) are reported. Failure is the proportion of patients who died or had lung transplant over 52 weeks (373 days time-period).

Time frame:
52 weeks
Reported as:
Number · percentage of participants
Time to Death or Lung Transplant Over 52 Weeks
percentage of participantsPlaceboNintedanib 150 mg Bid
Failure10.06.7
Censored90.093.3
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Log Rank · p = 0.1664 · Hazard ratio (hr): 0.67 · 95% CI 0.37 to 1.21Nintedanib 150 mg bid versus Placebo
SecondaryTime to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.

Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death or lung transplant or qualifying for lung transplant over 52 weeks are reported. A patient was considered qualifying for lung transplant by the investigator if he or she fulfilled the following criteria: FVC \<45% predicted or Carbon monoxide diffusion capacity (DL(CO)) \<30% pred or Oxygen saturation on pulse oximetry (SpO2) \<88% at rest, at sea level (to be adapted for other heights). These criteria were evaluated by investigators judgement. Failure is the proportion of patients who died or had lung transplant or qualified for lung transplant over 52 weeks (373 days time-period).

Time frame:
52 weeks
Reported as:
Number · percentage of participants
Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.
percentage of participantsPlaceboNintedanib 150 mg Bid
Failure23.719.5
Censored76.380.5
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Log Rank · p = 0.2123 · Hazard ratio (hr): 0.80 · 95% CI 0.55 to 1.16Nintedanib 150 mg bid versus Placebo
SecondaryChange From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks

Means presented are the adjusted means. Adjusted mean is based on all analyzed patients in the model (not only patients with a change from baseline to week 52)

Time frame:
baseline and 52 weeks
Reported as:
Mean · percent of oxygen saturation
Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks
percent of oxygen saturationPlaceboNintedanib 150 mg Bid
Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks-0.66 ± 0.174-0.39 ± 0.149
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Mixed Models Analysis · p = 0.2032 · Mean difference (final values): 0.27 · 95% CI -0.15 to 0.69Within-patient errors are modelled by compound symmetry covariance matrix. Nintedanib 150 mg bid versus Placebo.
SecondaryChange From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks

Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).

Time frame:
baseline and 52 weeks
Reported as:
Mean · mmol/min/kPa
Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks
mmol/min/kPaPlaceboNintedanib 150 mg Bid
Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks-0.400 ± 0.0843-0.286 ± 0.0729
Statistical analysis
  • Placebo vs Nintedanib 150 mg Bid · Mixed Models Analysis · p = 0.2600 · Mean difference (final values): 0.113 · 95% CI -0.084 to 0.310Within-patient errors are modelled by compound symmetry covariance matrix. Nintedanib 150 mg bid versus Placebo.

Adverse events

Collected over From the first drug administration until 28 days after the last drug administration, up to 425 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—72/219 (32.9%)193/219 (88.1%)
Nintedanib 150mg Bid—98/329 (29.8%)308/329 (93.6%)
Most frequent serious events
Showing 10 of 155
Most frequent serious events
EventPlaceboNintedanib 150mg Bid
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders28/21922/329
PneumoniaInfections and infestations11/21918/329
Respiratory failureRespiratory, thoracic and mediastinal disorders5/2192/329
BronchitisInfections and infestations0/2196/329
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders3/2196/329
Respiratory tract infectionInfections and infestations3/2191/329
DyspnoeaRespiratory, thoracic and mediastinal disorders3/2192/329
HypoxiaRespiratory, thoracic and mediastinal disorders3/2194/329
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/2194/329
AnaemiaBlood and lymphatic system disorders2/2190/329
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPlaceboNintedanib 150mg Bid
DiarrhoeaGastrointestinal disorders39/219207/329
NauseaGastrointestinal disorders16/21986/329
NasopharyngitisInfections and infestations34/21948/329
CoughRespiratory, thoracic and mediastinal disorders31/21938/329
Decreased appetiteMetabolism and nutrition disorders10/21942/329
Weight decreasedInvestigations2/21937/329
Upper respiratory tract infectionInfections and infestations24/21930/329
VomitingGastrointestinal disorders7/21934/329
DyspnoeaRespiratory, thoracic and mediastinal disorders22/21925/329
FatigueGeneral disorders20/21926/329

Baseline characteristics

Treated Set (TS): The TS consisted of randomized patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.

Age, Continuous
Age, Continuous(years)PlaceboNintedanib 150 mg BidTotal
Mean67.1 ± 7.566.4 ± 7.966.6 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboNintedanib 150 mg BidTotal
Female4873121
Male171256427
08

Study locations

108 sites
  • 1199.34.10078 Boehringer Ingelheim Investigational Site
    Scottsdale, Arizona, United States
  • 1199.34.10086 Boehringer Ingelheim Investigational Site
    San Francisco, California, United States
  • 1199.34.10093 Boehringer Ingelheim Investigational Site
    Santa Barbara, California, United States
  • 1199.34.10077 Boehringer Ingelheim Investigational Site
    Stanford, California, United States
  • 1199.34.10083 Boehringer Ingelheim Investigational Site
    Torrance, California, United States
  • 1199.34.10080 Boehringer Ingelheim Investigational Site
    Stamford, Connecticut, United States
  • 1199.34.10087 Boehringer Ingelheim Investigational Site
    South Miami, Florida, United States
  • 1199.34.10100 Boehringer Ingelheim Investigational Site
    Austell, Georgia, United States
  • 1199.34.10075 Boehringer Ingelheim Investigational Site
    Chicago, Illinois, United States
  • 1199.34.10069 Boehringer Ingelheim Investigational Site
    Olathe, Kansas, United States
  • 1199.34.10090 Boehringer Ingelheim Investigational Site
    Lexington, Kentucky, United States
  • 1199.34.10079 Boehringer Ingelheim Investigational Site
    Rochester, Minnesota, United States
  • 1199.34.10067 Boehringer Ingelheim Investigational Site
    Chesterfield, Missouri, United States
  • 1199.34.10066 Boehringer Ingelheim Investigational Site
    Lebanon, New Hampshire, United States
  • 1199.34.10085 Boehringer Ingelheim Investigational Site
    Albany, New York, United States
  • 1199.34.10092 Boehringer Ingelheim Investigational Site
    Jamaica, New York, United States
  • 1199.34.10074 Boehringer Ingelheim Investigational Site
    Durham, North Carolina, United States
  • 1199.34.10088 Boehringer Ingelheim Investigational Site
    Toledo, Ohio, United States
  • 1199.34.10070 Boehringer Ingelheim Investigational Site
    Portland, Oregon, United States
  • 1199.34.10064 Boehringer Ingelheim Investigational Site
    Philadelphia, Pennsylvania, United States
  • 1199.34.10089 Boehringer Ingelheim Investigational Site
    Philadelphia, Pennsylvania, United States
  • 1199.34.10082 Boehringer Ingelheim Investigational Site
    Charleston, South Carolina, United States
  • 1199.34.10095 Boehringer Ingelheim Investigational Site
    Longview, Texas, United States
  • 1199.34.10060 Boehringer Ingelheim Investigational Site
    San Antonio, Texas, United States
  • 1199.34.10084 Boehringer Ingelheim Investigational Site
    Salt Lake City, Utah, United States
  • 1199.34.10101 Boehringer Ingelheim Investigational Site
    Colchester, Vermont, United States
  • 1199.34.10073 Boehringer Ingelheim Investigational Site
    Madison, Wisconsin, United States
  • 1199.34.02001 Boehringer Ingelheim Investigational Site
    Calgary, Alberta, Canada
  • 1199.34.02003 Boehringer Ingelheim Investigational Site
    Halifax, Nova Scotia, Canada
  • 1199.34.02002 Boehringer Ingelheim Investigational Site
    Hamilton, Ontario, Canada
  • 1199.34.56001 Boehringer Ingelheim Investigational Site
    Santiago de Chile, Chile
  • 1199.34.86056 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 1199.34.86052 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 1199.34.86054 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 1199.34.86055 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 1199.34.86058 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 1199.34.86051 Boehringer Ingelheim Investigational Site
    Shenyang, China
  • 1199.34.86053 Boehringer Ingelheim Investigational Site
    Shenyang, China
  • 1199.34.86057 Boehringer Ingelheim Investigational Site
    Yinchuan, China
  • 1199.34.35801 Boehringer Ingelheim Investigational Site
    Helsinki, Finland
  • 1199.34.33004 Boehringer Ingelheim Investigational Site
    Dijon Cedex, France
  • 1199.34.33003 Boehringer Ingelheim Investigational Site
    Lille Cedex, France
  • 1199.34.33005 Boehringer Ingelheim Investigational Site
    Lyon Cedex, France
  • 1199.34.33007 Boehringer Ingelheim Investigational Site
    Marseille, France
  • 1199.34.33002 Boehringer Ingelheim Investigational Site
    Montpellier cedex 5, France
  • 1199.34.33006 Boehringer Ingelheim Investigational Site
    Toulouse cedex 9, France
  • 1199.34.49003 Boehringer Ingelheim Investigational Site
    Bad Berka, Germany
  • 1199.34.49010 Boehringer Ingelheim Investigational Site
    Berlin-Buch, Germany
  • 1199.34.49002 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 1199.34.49005 Boehringer Ingelheim Investigational Site
    Coswig, Germany
  • 1199.34.49001 Boehringer Ingelheim Investigational Site
    Essen, Germany
  • 1199.34.49007 Boehringer Ingelheim Investigational Site
    Greifswald, Germany
  • 1199.34.49009 Boehringer Ingelheim Investigational Site
    Immenhausen, Germany
  • 1199.34.49011 Boehringer Ingelheim Investigational Site
    Köln, Germany
  • 1199.34.49006 Boehringer Ingelheim Investigational Site
    München, Germany
  • 1199.34.49004 Boehringer Ingelheim Investigational Site
    Münster, Germany
  • 1199.34.30005 Boehringer Ingelheim Investigational Site
    Athens, Greece
  • 1199.34.30001 Boehringer Ingelheim Investigational Site
    Heraklion, Greece
  • 1199.34.30004 Boehringer Ingelheim Investigational Site
    Larisa, Greece
  • 1199.34.30002 Boehringer Ingelheim Investigational Site
    Maroussi, Athens, Greece
  • 1199.34.30003 Boehringer Ingelheim Investigational Site
    Nikaia, Greece
  • 1199.34.91051 Boehringer Ingelheim Investigational Site
    Ahmedabad, India
  • 1199.34.91053 Boehringer Ingelheim Investigational Site
    Banglore, India
  • 1199.34.91056 Boehringer Ingelheim Investigational Site
    Jaipur, India
  • 1199.34.91054 Boehringer Ingelheim Investigational Site
    Pune, India
  • 1199.34.91055 Boehringer Ingelheim Investigational Site
    Pune, India
  • 1199.34.81059 Boehringer Ingelheim Investigational Site
    Himeji, Hyogo, Japan
  • 1199.34.81063 Boehringer Ingelheim Investigational Site
    Kawasaki, Kanagawa, Japan
  • 1199.34.81060 Boehringer Ingelheim Investigational Site
    Kobe, Hyogo, Japan
  • 1199.34.81051 Boehringer Ingelheim Investigational Site
    Minato-ku, Tokyo, Japan
  • 1199.34.81054 Boehringer Ingelheim Investigational Site
    Nagoya, Aichi, Japan
  • 1199.34.81055 Boehringer Ingelheim Investigational Site
    Ogaki, Gifu, Japan
  • 1199.34.81058 Boehringer Ingelheim Investigational Site
    Osaka-Sayama, Osaka, Japan
  • 1199.34.81057 Boehringer Ingelheim Investigational Site
    Sakai, Osaka, Japan
  • 1199.34.81053 Boehringer Ingelheim Investigational Site
    Seto, Aichi, Japan
  • 1199.34.81052 Boehringer Ingelheim Investigational Site
    Shinjuku-ku, Tokyo, Japan
  • 1199.34.81056 Boehringer Ingelheim Investigational Site
    Tenri, Nara, Japan
  • 1199.34.81062 Boehringer Ingelheim Investigational Site
    Tokushima, Tokushima, Japan
  • 1199.34.81061 Boehringer Ingelheim Investigational Site
    Yonago, Tottori, Japan
  • 1199.34.82002 Boehringer Ingelheim Investigational Site
    Bucheon, Korea, Republic of
  • 1199.34.82004 Boehringer Ingelheim Investigational Site
    Incheon, Korea, Republic of
  • 1199.34.82001 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1199.34.82003 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1199.34.82006 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1199.34.82007 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 1199.34.52001 Boehringer Ingelheim Investigational Site
    Mexico DF, Mexico
  • 1199.34.31002 Boehringer Ingelheim Investigational Site
    Amsterdam, Netherlands
  • 1199.34.31001 Boehringer Ingelheim Investigational Site
    Nieuwegein, Netherlands
  • 1199.34.31003 Boehringer Ingelheim Investigational Site
    Rotterdam, Netherlands
  • 1199.34.35107 Boehringer Ingelheim Investigational Site
    Amadora, Portugal
  • 1199.34.35105 Boehringer Ingelheim Investigational Site
    Coimbra, Portugal
  • 1199.34.35102 Boehringer Ingelheim Investigational Site
    Lisboa, Portugal
  • 1199.34.35103 Boehringer Ingelheim Investigational Site
    Lisboa, Portugal
  • 1199.34.35101 Boehringer Ingelheim Investigational Site
    Porto, Portugal
  • 1199.34.35106 Boehringer Ingelheim Investigational Site
    Vila Nova de Gaia, Portugal
  • 1199.34.07001 Boehringer Ingelheim Investigational Site
    Kazan, Russian Federation
  • 1199.34.07003 Boehringer Ingelheim Investigational Site
    St. Petersburg, Russian Federation
  • 1199.34.34001 Boehringer Ingelheim Investigational Site
    Barcelona, Spain
  • 1199.34.34003 Boehringer Ingelheim Investigational Site
    Barcelona, Spain
  • 1199.34.34004 Boehringer Ingelheim Investigational Site
    Barcelona, Spain

Showing the first 100 of 108 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Glaspole I, Bonella F, Bargagli E, Glassberg MK, Caro F, Stansen W, Quaresma M, Orsatti L, Bendstrup E. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities. Respir Res. 2021 Apr 26;22(1):125. doi: 10.1186/s12931-021-01695-y. PubMed 33902584 ↗
  • Jouneau S, Crestani B, Thibault R, Lederlin M, Vernhet L, Valenzuela C, Wijsenbeek M, Kreuter M, Stansen W, Quaresma M, Cottin V. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respir Res. 2020 Nov 25;21(1):312. doi: 10.1186/s12931-020-01528-4. PubMed 33239000 ↗
  • Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, Goeldner RG, Clerisme-Beaty E, Tetzlaff K, Cottin V, Wells AU. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020 Jun 25;55(6):2000085. doi: 10.1183/13993003.00085-2020. Print 2020 Jun. PubMed 32217654 ↗
  • Richeldi L, Kolb M, Jouneau S, Wuyts WA, Schinzel B, Stowasser S, Quaresma M, Raghu G. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020 Jan 8;20(1):3. doi: 10.1186/s12890-019-1030-4. PubMed 31914963 ↗
  • Kreuter M, Koegler H, Trampisch M, Geier S, Richeldi L. Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS(R) trials. Respir Res. 2019 Apr 11;20(1):71. doi: 10.1186/s12931-019-1037-7. PubMed 30971229 ↗
  • Xu Z, Li H, Wen F, Bai C, Chen P, Fan F, Hu N, Stowasser S, Kang J. Subgroup Analysis for Chinese Patients Included in the INPULSIS(R) Trials on Nintedanib in Idiopathic Pulmonary Fibrosis. Adv Ther. 2019 Mar;36(3):621-631. doi: 10.1007/s12325-019-0887-1. Epub 2019 Feb 7. PubMed 30729456 ↗
  • Costabel U, Behr J, Crestani B, Stansen W, Schlenker-Herceg R, Stowasser S, Raghu G. Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS(R) trials. Respir Res. 2018 Sep 3;19(1):167. doi: 10.1186/s12931-018-0866-0. PubMed 30176872 ↗
  • Collard HR, Richeldi L, Kim DS, Taniguchi H, Tschoepe I, Luisetti M, Roman J, Tino G, Schlenker-Herceg R, Hallmann C, du Bois RM. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J. 2017 May 19;49(5):1601339. doi: 10.1183/13993003.01339-2016. Print 2017 May. PubMed 28526798 ↗
  • Paterniti MO, Bi Y, Rekic D, Wang Y, Karimi-Shah BA, Chowdhury BA. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2017 Sep;14(9):1395-1402. doi: 10.1513/AnnalsATS.201606-458OC. PubMed 28388260 ↗
  • Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. Pharmacoeconomics. 2017 Apr;35(4):479-491. doi: 10.1007/s40273-016-0480-2. PubMed 28039616 ↗
  • Kolb M, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, Hallmann C, du Bois RM. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017 Apr;72(4):340-346. doi: 10.1136/thoraxjnl-2016-208710. Epub 2016 Sep 26. PubMed 27672117 ↗
  • Corte T, Bonella F, Crestani B, Demedts MG, Richeldi L, Coeck C, Pelling K, Quaresma M, Lasky JA. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015 Sep 24;16:116. doi: 10.1186/s12931-015-0276-5. PubMed 26400368 ↗
  • Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. Erratum In: N Engl J Med. 2015 Aug 20;373(8):782. doi: 10.1056/NEJMx150012. PubMed 24836310 ↗
  • Richeldi L, Cottin V, Flaherty KR, Kolb M, Inoue Y, Raghu G, Taniguchi H, Hansell DM, Nicholson AG, Le Maulf F, Stowasser S, Collard HR. Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med. 2014 Jul;108(7):1023-30. doi: 10.1016/j.rmed.2014.04.011. Epub 2014 Apr 29. PubMed 24834811 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 1 year 4 months after primary completion. A results delay was requested in Mar 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2011
First posted
Apr 14, 2011
Start
May 2011
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results delay requested
Mar 28, 2014
Results first posted
Feb 13, 2015
Last update
Jul 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01335477
Responsible party
Sponsor
First posted
Apr 14, 2011
Start date
May 2011
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Feb 13, 2015
Last update
Jul 25, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion